TY - JOUR
T1 - Efficacy of Daclizumab in an African-American and Hispanic renal transplant population
AU - Meier-Kriesche, Herwig Ulf
AU - Palenkar, Sadanand S.
AU - Friedman, Gary S.
AU - Mulgaonkar, Shamkant P.
AU - Goldblat, Melvin V.
AU - Kaplan, Bruce
PY - 2000/3
Y1 - 2000/3
N2 - Current immunosuppressive regimens have decreased acute rejection rates during the 1st year after renal transplantation. However, this decrease has not been as marked in high-risk groups, such as African-American and Hispanic renal transplant recipients. We compared two simultaneous cohorts of altogether 36 African-American and Hispanic renal transplant recipients. Cohort one received a regimen of mycophenolate mofetil, prednisone, and a calcineurin inhibitor. The second cohort received the same protocol with the addition of Daclizumab (1 mg/kg for five doses given every 2 weeks). The median follow-up was 15.2 months (range 11.8-19.9 months). One patient in the Daclizumab-treated group and seven patients in the control group experienced an acute rejection episode. The rejection-free survival was significantly higher in the Daclizumab-treated group (94.4%) (66.7%, Log-rank < 0.05) at 17 months after transplantation. A Cox Proportional Hazard model revealed lack of Daclizumab therapy as the only significant risk factor for acute rejection. (hazard ratio 7.0, 95% CI = 1.1-48). The addition of the IL-2 receptor blocker Daclizumab to a triple therapy regimen may decrease early acute rejection in the high-risk groups of African-American and Hispanic patients.
AB - Current immunosuppressive regimens have decreased acute rejection rates during the 1st year after renal transplantation. However, this decrease has not been as marked in high-risk groups, such as African-American and Hispanic renal transplant recipients. We compared two simultaneous cohorts of altogether 36 African-American and Hispanic renal transplant recipients. Cohort one received a regimen of mycophenolate mofetil, prednisone, and a calcineurin inhibitor. The second cohort received the same protocol with the addition of Daclizumab (1 mg/kg for five doses given every 2 weeks). The median follow-up was 15.2 months (range 11.8-19.9 months). One patient in the Daclizumab-treated group and seven patients in the control group experienced an acute rejection episode. The rejection-free survival was significantly higher in the Daclizumab-treated group (94.4%) (66.7%, Log-rank < 0.05) at 17 months after transplantation. A Cox Proportional Hazard model revealed lack of Daclizumab therapy as the only significant risk factor for acute rejection. (hazard ratio 7.0, 95% CI = 1.1-48). The addition of the IL-2 receptor blocker Daclizumab to a triple therapy regimen may decrease early acute rejection in the high-risk groups of African-American and Hispanic patients.
KW - Daclizumab
KW - High-risk population
KW - Immunosuppression
KW - Kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=0034047643&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034047643&partnerID=8YFLogxK
U2 - 10.1007/s001470050675
DO - 10.1007/s001470050675
M3 - Article
C2 - 10836651
AN - SCOPUS:0034047643
SN - 0934-0874
VL - 13
SP - 142
EP - 145
JO - Transplant International
JF - Transplant International
IS - 2
ER -